COMP <GO>
KBR vs TMO // RSI-14 & 200D SMA MOMENTUM
KBR Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: KBR 7
— TMO 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: KBR
LAST: $38.70 (+0.99%) • MKT CAP: $4.83B
rsi-technicals
59.5
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
rsi-technicals
59.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KBR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KBR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.80% | 41.00% | -26.20 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.30% | 9.30% | +8.00 | KBR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 8.5x | 30.4x | -21.90 | KBR | /valuation <GO> |
| Free Cash Flow Yield | 8.92% | 2.40% | +6.52 | KBR | /fcf-yield <GO> |
| Operating Margin | 10.00% | 17.40% | -7.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 5.30% | 15.10% | -9.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 1.00% | 3.90% | -2.90 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.74% | 0.24% | +1.50 | KBR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.57 | 4.50 | -1.93 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.70% | +0.60 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 59.5 | 59.1 | +0.34 | KBR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.94 | +0.17 | KBR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.8x | 36.3x | -25.50 | KBR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.83B | $262.22B | -$257.39B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KBR REV | TMO REV | KBR GROSS % | TMO GROSS % | KBR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.79B | $44.56B | 14.8% | 44.0% | $422.8M | $6.29B |
| FY 2024 | $7.71B | $42.88B | 14.3% | 44.0% | $410.0M | $7.27B |
| FY 2023 | $6.96B | $42.86B | 44.0% | 44.0% | $18.0M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KBR // BETA 1.11
TMO // BETA 0.94